These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19018870)

  • 1. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
    Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Minauchi K; Yamaguchi K; Takeda Y; Sato N; Koizumi K; Mukai M; Koike T
    Eur J Haematol; 2006 Sep; 77(3):226-32. PubMed ID: 16923109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
    Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
    Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
    Shortt J; Spencer A
    Bone Marrow Transplant; 2006 Sep; 38(6):433-6. PubMed ID: 16892074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
    Liu F; Ding H; Jin X; Ding N; Deng L; He Y; Zhu J; Song Y
    DNA Cell Biol; 2014 Sep; 33(9):616-23. PubMed ID: 25050883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
    Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
    Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
    Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma.
    Yusuf RZ; Dey B; Yeap BY; McAfee S; Attar E; Sepe PS; Dube C; Spitzer TR; Ballen KK
    Bone Marrow Transplant; 2009 Jan; 43(1):37-42. PubMed ID: 18794868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's lymphoma.
    Verdonck LF
    J Clin Oncol; 1999 Sep; 17(9):3003. PubMed ID: 10627188
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
    Ataergin S; Arpaci F; Beyzadeoglu M; Safali M; Ozet A
    Am J Hematol; 2006 Dec; 81(12):986-7. PubMed ID: 16886214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.